The latest drug to bite the dust is LY2886721, a beta secretase, or BACE, inhibitor. Eli Lilly stopped a phase 2 trial after some patients had abnormal liver biochemical tests. Companies routinely run liver tests on clinical trial patients because it's one of the most common safety issues that affect drugs. The liver's job, after all, is to filter toxins out of the blood stream.
DRUG DEVELOPMENT DECONSTRUCTOR MANIFESTO: : “Tell me how you read and I'll tell you who you are.” ― Martin Heidegger
No comments:
Post a Comment